The higher expression of MLL1 in pancreatic cancer enhances PD-L1(CD274) expression by increasing H3K4me3 status at the CD274 promoter region, thereby helping pancreatic cancer escape anti-PD-L1/PD-1 immunotherapy [173]. This evidence concerns the gene KMT2A and pancreatic neoplasm.